Objectives: We aimed to evaluate the prevalence of irritable bowel syndrome (IBS) in patients with typical reflux symptoms as distinguished into gastroesophageal reflux disease (GERD), hypersensitive esophagus (HE), and functional heartburn (FH) by means of endoscopy and multichannel intraluminal impedance (MII)-pH monitoring. The secondary aim was to detect pathophysiological and clinical differences between different sub-groups of patients with heartburn.
Methods: Patients underwent a structured interview based on questionnaires for GERD, IBS, anxiety, and depression. Off-therapy upper-gastrointestinal (GI) endoscopy and 24 h MII-pH monitoring were performed in all cases. In patients with IBS, fecal calprotectin was measured and colonoscopy was scheduled for values >100 mg/kg to exclude organic disease. Multivariate logistic regression analysis was performed to identify independent risk factors for FH.
Results: Of the 697 consecutive heartburn patients who entered the study, 454 (65%) had reflux-related heartburn (GERD+HE), whereas 243 (35%) had FH. IBS was found in 147/454 (33%) GERD/HE but in 187/243 (77%) FH patients (P<0.001). At multivariate analysis, IBS and anxiety were independent risk factors for FH in comparison with reflux-related heartburn (GERD+HE).
Conclusions: IBS overlaps more frequently with FH than with GERD and HE, suggesting common pathways and treatment. HE showed intermediate characteristic between GERD and FH.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/ajg.2016.432 | DOI Listing |
J Family Med Prim Care
December 2024
Nursing Tutor, Vardhman Mahaveer Nursing Medical College, New Delhi, India.
Background: Post-acute coronavirus disease 2019 (COVID-19) syndrome (PACS) is the persistence of sequel of acute SARS-COV-2 infection. Persistent/acquired gastrointestinal symptoms (GI-PACS) include loss of appetite, nausea, weight loss, abdominal pain, heartburn, dysphagia, altered bowel motility, dyspepsia, and irritable bowel syndrome. The study aimed to assess the short- and long-term GI-PACS syndrome on the GSRS scale.
View Article and Find Full Text PDFExpert Rev Gastroenterol Hepatol
January 2025
Department of Gastroenterology & Hepatology, Amsterdam University Medical Center, Amsterdam, the Netherlands.
Introduction: Surgical gastric fundoplication is an effective treatment option for gastroesophageal reflux disease. In contrast to acid suppression, fundoplication nearly abolishes all types of reflux, acid and nonacid. However, in some cases lasting side effects of the procedure may overshadow its positive effects.
View Article and Find Full Text PDFClin Physiol Funct Imaging
January 2025
Sydney Heartburn Clinic, Lindfield, New South Wales, Australia.
Introduction: Laryngopharyngeal reflux (LPR) management guidelines are currently derived from the management of gastroesophageal reflux disease (GORD) which has been shown to be poorly effective in controlling symptoms for these patients. Erythromycin is a macrolide antibiotic that has been used extensively as a prokinetic agent for the gastrointestinal tract. The management of LPR with prokinetics is a novel therapy being investigated with regard to its effectiveness.
View Article and Find Full Text PDFJ Educ Health Promot
October 2024
Department of Physiology, Symbiosis Medical College for Women, Symbiosis International University, Pune, Maharashtra, India.
Background: The relationship between the mind, gut, and sleep is not static and requires proper harmony for optimal emotional health. Recent evidence suggests that gut health is a key player in regulating mental and physical health via bidirectional communication between the brain and gut.
Materials And Methods: A cross-sectional comparative study was undertaken on 200 participants aged 25-40 years old for two months at a tertiary care hospital.
Dig Dis Sci
December 2024
Surgical Department, Fejér County Szent György University Teaching Hospital, Székesfehérvár, Hungary.
Background: RefluxStop is a unique implant for laparoscopic treatment of gastroesophageal reflux disease (GERD). It restores normal function of the gastroesophageal junction without the unwanted effects of encircling the esophagus, circumventing adverse events (AEs) associated with conventional anti-reflux surgeries.
Methods: Three-year follow-up of 50 patients with chronic GERD treated by RefluxStop was achieved in a prospective, single-arm, multicentric clinical trial analyzing safety and effectiveness of the procedure.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!